Zhang, Shaoyang http://orcid.org/0000-0002-0888-5240
Guo, Xuemin http://orcid.org/0000-0003-2929-7461
Liu, Xiufeng http://orcid.org/0000-0001-5407-3174
Zhong, Zhixiong http://orcid.org/0000-0002-3200-3105
Yang, Shulan http://orcid.org/0000-0002-6864-2195
Wang, Haihe http://orcid.org/0000-0002-9302-2334
Funding for this research was provided by:
National Natural Science Foundation of China (No. 81672704)
Article History
Received: 17 February 2021
Revised: 11 July 2021
Accepted: 19 July 2021
First Online: 30 July 2021
Change Date: 20 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-021-02129-1
Competing interests
: Drs. Haihe Wang and Shulan Yang, researchers on the study team, are co-inventors on Patent 201710512823.6 (Sun Yat-sen University) which deals with the application of SH3BGRL as a diagnostic and therapy target. No other authors have competing interests.